glp 1 drug mechanism of action Frontiers GLP1-GIP receptor co-agonists: a promising

The biologics segment is likely to grow significantly during the forecast period

Tirzepatide is also contraindicated in individuals with a history of multiple endocrine neoplasia syndrome Type-2 (MEN 2)

Consistent use is associated with fewer adverse events than intermittent use

Proper dosing schedules become essential because higher doses lead to more frequent side effects such as gastrointestinal upset, and the side effects can be managed by using the minimum effective dose or slow titration (Figure 2)

The use of GLP-1 RA was associated with a higher incidence of thyroid cancer (TC), specifically medullary TC, after one to three years of treatment, according to Bezin et al

Results are expected in late 2025